BeOne Medicines Ltd.

Total Valuation

BeOne Medicines Ltd. carries a market capitalization of 29.81B, placing it among publicly traded companies globally. Its enterprise value stands at 29.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BeOne Medicines Ltd. currently has 1.45B shares outstanding.

Valuation Ratios

BeOne Medicines Ltd. trades at a trailing price-to-earnings ratio of 63.71. The price-to-sales ratio is 5.69, and the price-to-book ratio stands at -4.04.

Enterprise Valuation

On an enterprise value basis, BeOne Medicines Ltd. trades at an EV/EBITDA multiple of 34.74 and an EV/FCF ratio of 19.34. The EV/Sales ratio of 5.06 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 42.34 provides insight into valuation relative to core operating earnings.

Financial Position

BeOne Medicines Ltd. maintains a current ratio of 3.64, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.13, indicating elevated leverage, while an interest coverage ratio of 25.42 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, BeOne Medicines Ltd. has paid 142.15M in income taxes, reflecting an effective tax rate of 21.70.

Stock Price Statistics

BeOne Medicines Ltd.'s stock has gained approximately 10.83744% over the past 52 weeks. The 50-day moving average sits at 301.35, while the 200-day moving average is 320.96.

Income Statement

Over the trailing twelve months, BeOne Medicines Ltd. generated 5.74B in revenue and converted that into 513.02M in net income, yielding earnings per share of 4.48. EBITDA reached 835.96M, while operating income came in at 685.94M.

Balance Sheet

BeOne Medicines Ltd. holds 4.79B in cash and equivalents against 1.15B in total debt, resulting in a net debt position of -3.71B. Total book value stands at -8.09B, with working capital of 4.79B providing operational flexibility.

Cash Flow

BeOne Medicines Ltd. produced 1.28B in operating cash flow over the past twelve months. After subtracting -190.91M in capital expenditures, free cash flow totaled 1.09B - equivalent to 9.94 per share.

Margins

BeOne Medicines Ltd. operates with a gross margin of 88.31, reflecting its pricing power and cost economics. The operating margin of 11.95 and net profit margin of 8.94 provide insight into operational efficiency.

Dividends & Yields

Scores

BeOne Medicines Ltd. posts an Altman Z-Score of 5.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.